35. 天疱瘡 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 120 / 薬物数 : 109 - (DrugBank : 40) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 167
薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
A single blood sample FOR HLA typing
Sechenov University
2017 - NCT05284929 Russian Federation
AB-101
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
Acetaminophen/paracetamol
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
AD26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
ALXN1830
Alexion Pharmaceuticals
2017 Phase 1/Phase 2 NCT03075904 United States
ARGX-113
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx
2017 Phase 2 NCT03334058 Germany;Hungary;Israel;Italy;Ukraine
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine
Autologous platelet rich plasma
Cairo University
2016 Phase 3 NCT02828163 Egypt
Azathioprine
Dermatological Department, West China hospital, Sichuan University
2016 Phase 1 study ChiCTR-OIC-17011759 China
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of
B007
Shanghai Jiaolian Drug Research and Development Co., Ltd
2024 Phase 2/Phase 3 NCT06454357 China
Bifidobacterium
The Second Xiangya Hospital of Central South University
2024 Phase 4 ChiCTR2400087412 China
BNT162b2, bivalent
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Carboxymethylcellulose
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Cellcept 500 MG comprimidos recubiertos
Aspreva pharmaceuticals Corporation
2006 Phase 3 EUCTR2004-000526-75-ES Spain
Cellcept® IN autoimmune bullous dermatoses
University Hospital, Limoges
2016 Phase 3 NCT02993133 France
Cellcept®500 MG comprimidos
Aspreva pharmaceuticals Corporation
2006 Phase 3 EUCTR2004-000526-75-ES Spain
Cellulose acetate with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Cetirizine
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
CM313 injection
Sichuan Provincial People's Hospital
2025 - NCT06904040 China
Cohort 1: 1.0 X 10^8 polytregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States
Cohort 2: 2.5x10^8 polytregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States
Combination OF protein A immunoadsorption, rituximab, dexamethasone plus azathioprine
University of Luebeck
2008 Phase 2 NCT00656656 Germany
Cortancyl 20 MG
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
2009 - EUCTR2008-005266-31-FR France
Corticosteroids'therapy
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
Cotton gauze with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Cyclophosphamide
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
Johns Hopkins University
1999 Phase 2 NCT00010413 United States
New York University School of Medicine
2007 Phase 2 NCT00483119 United States
Dapsone
Jacobus Pharmaceutical
1996 Phase 2 NCT00429533 United States
Dermoval
University Hospital, Rouen
2001 - NCT00213421 France
Dexamethasone
University Medical Centre Groningen
2001 Phase 2/Phase 3 NCT00127764 Netherlands
Dexamethasone 0.5MG/5ML solution
University of California, San Francisco
2020 Phase 2 NCT04540133 United States
Dexamethasone azathioprine pulse therapy
Jinnah Postgraduate Medical Centre
2021 Phase 4 NCT06846255 Pakistan
Dexamethasone cyclophosphamide pulse therapy
Jinnah Postgraduate Medical Centre
2021 Phase 4 NCT06846255 Pakistan
DSG3-caart or CABA-201
Cabaletta Bio
2020 Phase 1 NCT04422912 United States
Efgartigimod
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine
Efgartigimod alfa
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Etanercept
Massachusetts General Hospital
2004 Phase 2 NCT00135720 United States
Filgrastim
Johns Hopkins University
1999 Phase 2 NCT00010413 United States
Fludarabine
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
General corticotherapy
University Hospital, Rouen
2009 Phase 3 NCT00784589 France
Glucocorticoids
Chao Ji
2025 Phase 1/Phase 2 NCT06663943 -
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003539 China
Sichuan Provincial People's Hospital
2025 - NCT06904040 China
Glycine
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany
GSK1841157
Glaxo Group Ltd
2015 Phase 3 EUCTR2013-001370-20-PL Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2015 - EUCTR2013-001370-20-FR Australia;China;Croatia;France;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-IT Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-GR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
Novartis Pharma AG
2014 Phase 3 EUCTR2013-001370-20-HR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
Hematopoietic stem cell transplantation
Richard Burt, MD
2002 Phase 1 NCT00278642 United States
Ianalumab
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States
Imatinib
Kabashima Kenji
2018 Phase 0 JPRN-jRCTs051180069 -
INCB050465 0.3 MG
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
INCB050465 0.3MG
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
INCB050465 1.0 MG
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
INCB050465 1.0MG
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
INCB050465 2.5MG
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
INCB050465 hydrochloride
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
Infliximab
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Phase 2 NCT00283712 United States
Interleukin 2
The First Affiliated Hospital of Nanchang University
2023 Phase 4 ChiCTR2500099202 China
Intratect
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany
Intravenous immunoglobulin
New York University School of Medicine
2007 Phase 2 NCT00483119 United States
Ivig
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong
KC706
Kemia, Inc
2007 Phase 2 NCT00606749 United States
LOW energy diode laser
Cairo University
2025 - NCT06971172 -
Mabthera
CHU de Rouen
2023 Phase 4 EUCTR2022-000060-22-FR France
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
ISTITUTO DERMOPATICO IMMACOLATA
2007 - EUCTR2007-005711-26-IT Italy
University Hospital, Rouen
2003 Phase 2/Phase 3 NCT00213512 France
University Hospital, Toulouse
2009 - NCT00960713 France
MabthéRA
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France
MathéRA
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France
Medication
Cairo University
2025 - NCT06971172 -
Methotrexate
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003539 China
Peking university first hospital
2024 - ChiCTR2400091904 China
Methylprednisolone
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China
Micofenolato mofetilo
Aspreva pharmaceuticals Corporation
2006 Phase 3 EUCTR2004-000526-75-ES Spain
MMF
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Moderna MRNA-1273, bivalent
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Monovalent [B.1.351] COV2 pres DTM-AS03
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
MPA
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
MTX
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China
2011 - ChiCTR-TRC-12003539 China
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Mupirocin
West China Hospital of Sichuan University
2023 - ChiCTR2500095607 China
Mycophenolate mofetil
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Hoffmann-La Roche
2015 Phase 3 NCT02383589 Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Shandong Provincial Hospital for Skin Diseases & Shandong First Medical University
2023 - ChiCTR2400090625 China
Mycophenolate mofetil (MMF) 3 G/DAY
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States
Mycophenolate mofetil 2 G/DAY
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States
Ofatumumab
Glaxo Group Ltd
2015 Phase 3 EUCTR2013-001370-20-PL Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2015 - EUCTR2013-001370-20-FR Australia;China;Croatia;France;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-IT Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-GR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
Novartis Pharma AG
2014 Phase 3 EUCTR2013-001370-20-HR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
Novartis Pharmaceuticals
2013 Phase 3 NCT01920477 Australia;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United States
Ofatumumab subcutaneous injection
Chao Ji
2023 - NCT06654817 China
ONO-4059
Ono Pharmaceutical Co. Ltd
2022 Phase 3 NCT06696716 Japan
Ozonated olive OIL
Cairo University
2022 Phase 3 NCT05594472 Egypt
Parsaclisib
Incyte Corporation
2019 Phase 2 NCT03780166 -
PI-0824
Peptimmune
2003 Phase 1 NCT00063752 United States
Prednison 10 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednison 5 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednison 50 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednison20 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednisone
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
2009 - EUCTR2008-005266-31-FR France
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China
2011 - ChiCTR-TRC-12003539 China
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Prednisone acetate
Department of Dermatology, the First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086721 China
The First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086698 China
Prednisone/prednisolone
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
PRN1008
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-HR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-GR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-GB Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-FR Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-ES Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2018 Phase 3 EUCTR2018-002261-19-BG Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
Principia Biopharma , Inc.
2019 Phase 3 EUCTR2018-002261-19-DE Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma Inc.
2019 Phase 3 EUCTR2018-002261-19-IT Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2016 Phase 2 NCT02704429 Australia;Croatia;France;Greece;Israel
PRN1008 freebase
Principia Biopharma Australia Pty Ltd
2016 Phase 2 EUCTR2015-003564-37-HR Australia;Croatia;France;Greece;Israel
2016 Phase 2 EUCTR2015-003564-37-GR Australia;Croatia;France;Greece;Israel
Prothrombin fragment 1+2
Assiut University
2024 - NCT06285435 -
Rapamycin
University of California, Irvine
2011 Early Phase 1 NCT01313923 United States
Recombinant human interleukin-2
Second Xiangya Hospital of Central South University
2020 Phase 2 NCT04023149 China
Rilzabrutinib
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-HR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-GB Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2018 Phase 3 EUCTR2018-002261-19-BG Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
Principia Biopharma , Inc.
2019 Phase 3 EUCTR2018-002261-19-DE Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Rilzabrutinib oral tablet
Principia Biopharma, a Sanofi Company
2019 Phase 3 NCT03762265 Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Rituxan
University Hospital, Toulouse
2009 - NCT00960713 France
Rituximab
CHU de Rouen
2023 Phase 4 EUCTR2022-000060-22-FR France
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
Department of Dermatology, Keio University School of Medicine
2016 Phase 2 JPRN-UMIN000024265 Japan
2014 Phase 1,2 JPRN-UMIN000015451 Japan
Dermatology Hospital of Southern Medical University
2022 - ChiCTR2200066662 China
Dermatology Hospital of Southern Medical University, Guangzhou, China
2021 Phase 0 ChiCTR2300069742 China
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Funakoshi Takeru
2017 - JPRN-jRCTs031180405 -
Hoffmann-La Roche
2015 Phase 3 NCT02383589 Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
ISTITUTO DERMOPATICO IMMACOLATA
2007 - EUCTR2007-005711-26-IT Italy
Kanaoka Miwa
2014 - JPRN-jRCTs031180220 -
Keio University, School of Medicine
2017 - JPRN-UMIN000026004 Japan
Peking University First Hospital
2022 Phase 4 ChiCTR2200062766 Beijing
Rabin Medical Center
2010 - NCT01338103 Israel
Research group of rare intractable dermatologial disorder
2010 Phase 2 JPRN-UMIN000004428 Japan
Shandong Provincial Hospital for Skin Diseases & Shandong First Medical University
2023 - ChiCTR2400090625 China
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
2011 Phase 3 NCT01299857 France
2009 Phase 3 NCT00784589 France
University Hospital, Toulouse
2009 - NCT00960713 France
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China
Rituximab and cyclophosphamide IV
Uprety Shraddha
2013 Phase 3 NCT01974518 India
Rituximab injection
University Hospital, Rouen
2023 Phase 4 NCT05898308 -
RO0452294/V02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
RO1061443/F02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Silver
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Sirolimus
University of California, Irvine
2011 Early Phase 1 NCT01313923 United States
Tofacitinib
Department of Dermatology, the First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086721 China
The First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086698 China
Topical garamycin cream
Cairo University
2022 Phase 3 NCT05594472 Egypt
TPM203
Topas Therapeutics GmbH
2019 Phase 1 EUCTR2019-001727-12-DE Germany;Israel;Italy;United Kingdom
Triamcinolone acetonide
Cairo University
2016 Phase 3 NCT02828163 Egypt
VAY736
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States
Novartis Pharmaceuticals
2013 Phase 2 NCT01930175 Austria;Bulgaria;Germany;Israel;Italy;Taiwan;United Kingdom;United States
Water FOR injection
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany
Sechenov University
2017 - NCT05284929 Russian Federation
AB-101
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
Acetaminophen/paracetamol
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
AD26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
ALXN1830
Alexion Pharmaceuticals
2017 Phase 1/Phase 2 NCT03075904 United States
ARGX-113
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx
2017 Phase 2 NCT03334058 Germany;Hungary;Israel;Italy;Ukraine
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine
Autologous platelet rich plasma
Cairo University
2016 Phase 3 NCT02828163 Egypt
Azathioprine
Dermatological Department, West China hospital, Sichuan University
2016 Phase 1 study ChiCTR-OIC-17011759 China
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of
B007
Shanghai Jiaolian Drug Research and Development Co., Ltd
2024 Phase 2/Phase 3 NCT06454357 China
Bifidobacterium
The Second Xiangya Hospital of Central South University
2024 Phase 4 ChiCTR2400087412 China
BNT162b2, bivalent
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Carboxymethylcellulose
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Cellcept 500 MG comprimidos recubiertos
Aspreva pharmaceuticals Corporation
2006 Phase 3 EUCTR2004-000526-75-ES Spain
Cellcept® IN autoimmune bullous dermatoses
University Hospital, Limoges
2016 Phase 3 NCT02993133 France
Cellcept®500 MG comprimidos
Aspreva pharmaceuticals Corporation
2006 Phase 3 EUCTR2004-000526-75-ES Spain
Cellulose acetate with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Cetirizine
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
CM313 injection
Sichuan Provincial People's Hospital
2025 - NCT06904040 China
Cohort 1: 1.0 X 10^8 polytregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States
Cohort 2: 2.5x10^8 polytregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States
Combination OF protein A immunoadsorption, rituximab, dexamethasone plus azathioprine
University of Luebeck
2008 Phase 2 NCT00656656 Germany
Cortancyl 20 MG
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
2009 - EUCTR2008-005266-31-FR France
Corticosteroids'therapy
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
Cotton gauze with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Cyclophosphamide
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
Johns Hopkins University
1999 Phase 2 NCT00010413 United States
New York University School of Medicine
2007 Phase 2 NCT00483119 United States
Dapsone
Jacobus Pharmaceutical
1996 Phase 2 NCT00429533 United States
Dermoval
University Hospital, Rouen
2001 - NCT00213421 France
Dexamethasone
University Medical Centre Groningen
2001 Phase 2/Phase 3 NCT00127764 Netherlands
Dexamethasone 0.5MG/5ML solution
University of California, San Francisco
2020 Phase 2 NCT04540133 United States
Dexamethasone azathioprine pulse therapy
Jinnah Postgraduate Medical Centre
2021 Phase 4 NCT06846255 Pakistan
Dexamethasone cyclophosphamide pulse therapy
Jinnah Postgraduate Medical Centre
2021 Phase 4 NCT06846255 Pakistan
DSG3-caart or CABA-201
Cabaletta Bio
2020 Phase 1 NCT04422912 United States
Efgartigimod
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine
Efgartigimod alfa
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;China;Croatia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-ES Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Etanercept
Massachusetts General Hospital
2004 Phase 2 NCT00135720 United States
Filgrastim
Johns Hopkins University
1999 Phase 2 NCT00010413 United States
Fludarabine
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
General corticotherapy
University Hospital, Rouen
2009 Phase 3 NCT00784589 France
Glucocorticoids
Chao Ji
2025 Phase 1/Phase 2 NCT06663943 -
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003539 China
Sichuan Provincial People's Hospital
2025 - NCT06904040 China
Glycine
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany
GSK1841157
Glaxo Group Ltd
2015 Phase 3 EUCTR2013-001370-20-PL Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2015 - EUCTR2013-001370-20-FR Australia;China;Croatia;France;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-IT Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-GR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
Novartis Pharma AG
2014 Phase 3 EUCTR2013-001370-20-HR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
Hematopoietic stem cell transplantation
Richard Burt, MD
2002 Phase 1 NCT00278642 United States
Ianalumab
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States
Imatinib
Kabashima Kenji
2018 Phase 0 JPRN-jRCTs051180069 -
INCB050465 0.3 MG
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
INCB050465 0.3MG
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
INCB050465 1.0 MG
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
INCB050465 1.0MG
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
INCB050465 2.5MG
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
INCB050465 hydrochloride
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy
Infliximab
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Phase 2 NCT00283712 United States
Interleukin 2
The First Affiliated Hospital of Nanchang University
2023 Phase 4 ChiCTR2500099202 China
Intratect
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany
Intravenous immunoglobulin
New York University School of Medicine
2007 Phase 2 NCT00483119 United States
Ivig
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong
KC706
Kemia, Inc
2007 Phase 2 NCT00606749 United States
LOW energy diode laser
Cairo University
2025 - NCT06971172 -
Mabthera
CHU de Rouen
2023 Phase 4 EUCTR2022-000060-22-FR France
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
ISTITUTO DERMOPATICO IMMACOLATA
2007 - EUCTR2007-005711-26-IT Italy
University Hospital, Rouen
2003 Phase 2/Phase 3 NCT00213512 France
University Hospital, Toulouse
2009 - NCT00960713 France
MabthéRA
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France
MathéRA
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France
Medication
Cairo University
2025 - NCT06971172 -
Methotrexate
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003539 China
Peking university first hospital
2024 - ChiCTR2400091904 China
Methylprednisolone
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China
Micofenolato mofetilo
Aspreva pharmaceuticals Corporation
2006 Phase 3 EUCTR2004-000526-75-ES Spain
MMF
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Moderna MRNA-1273, bivalent
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Monovalent [B.1.351] COV2 pres DTM-AS03
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
MPA
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
MTX
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China
2011 - ChiCTR-TRC-12003539 China
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States
Mupirocin
West China Hospital of Sichuan University
2023 - ChiCTR2500095607 China
Mycophenolate mofetil
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Hoffmann-La Roche
2015 Phase 3 NCT02383589 Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Shandong Provincial Hospital for Skin Diseases & Shandong First Medical University
2023 - ChiCTR2400090625 China
Mycophenolate mofetil (MMF) 3 G/DAY
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States
Mycophenolate mofetil 2 G/DAY
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States
Ofatumumab
Glaxo Group Ltd
2015 Phase 3 EUCTR2013-001370-20-PL Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2015 - EUCTR2013-001370-20-FR Australia;China;Croatia;France;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-IT Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
2014 Phase 3 EUCTR2013-001370-20-GR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
Novartis Pharma AG
2014 Phase 3 EUCTR2013-001370-20-HR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States
Novartis Pharmaceuticals
2013 Phase 3 NCT01920477 Australia;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United States
Ofatumumab subcutaneous injection
Chao Ji
2023 - NCT06654817 China
ONO-4059
Ono Pharmaceutical Co. Ltd
2022 Phase 3 NCT06696716 Japan
Ozonated olive OIL
Cairo University
2022 Phase 3 NCT05594472 Egypt
Parsaclisib
Incyte Corporation
2019 Phase 2 NCT03780166 -
PI-0824
Peptimmune
2003 Phase 1 NCT00063752 United States
Prednison 10 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednison 5 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednison 50 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednison20 MG galen
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Prednisone
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
2009 - EUCTR2008-005266-31-FR France
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China
2011 - ChiCTR-TRC-12003539 China
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Prednisone acetate
Department of Dermatology, the First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086721 China
The First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086698 China
Prednisone/prednisolone
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States
PRN1008
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-HR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-GR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-GB Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-FR Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-ES Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2018 Phase 3 EUCTR2018-002261-19-BG Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
Principia Biopharma , Inc.
2019 Phase 3 EUCTR2018-002261-19-DE Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma Inc.
2019 Phase 3 EUCTR2018-002261-19-IT Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2016 Phase 2 NCT02704429 Australia;Croatia;France;Greece;Israel
PRN1008 freebase
Principia Biopharma Australia Pty Ltd
2016 Phase 2 EUCTR2015-003564-37-HR Australia;Croatia;France;Greece;Israel
2016 Phase 2 EUCTR2015-003564-37-GR Australia;Croatia;France;Greece;Israel
Prothrombin fragment 1+2
Assiut University
2024 - NCT06285435 -
Rapamycin
University of California, Irvine
2011 Early Phase 1 NCT01313923 United States
Recombinant human interleukin-2
Second Xiangya Hospital of Central South University
2020 Phase 2 NCT04023149 China
Rilzabrutinib
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-HR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2018-002261-19-GB Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
2018 Phase 3 EUCTR2018-002261-19-BG Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States
Principia Biopharma , Inc.
2019 Phase 3 EUCTR2018-002261-19-DE Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Rilzabrutinib oral tablet
Principia Biopharma, a Sanofi Company
2019 Phase 3 NCT03762265 Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Rituxan
University Hospital, Toulouse
2009 - NCT00960713 France
Rituximab
CHU de Rouen
2023 Phase 4 EUCTR2022-000060-22-FR France
CHU-Hôpitaux de Rouen
2018 Phase 3 EUCTR2018-001417-32-FR France
Department of Dermatology, Keio University School of Medicine
2016 Phase 2 JPRN-UMIN000024265 Japan
2014 Phase 1,2 JPRN-UMIN000015451 Japan
Dermatology Hospital of Southern Medical University
2022 - ChiCTR2200066662 China
Dermatology Hospital of Southern Medical University, Guangzhou, China
2021 Phase 0 ChiCTR2300069742 China
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Funakoshi Takeru
2017 - JPRN-jRCTs031180405 -
Hoffmann-La Roche
2015 Phase 3 NCT02383589 Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
IRIS Research and Development, LLC
2024 Phase 1 NCT06581562 United States
ISTITUTO DERMOPATICO IMMACOLATA
2007 - EUCTR2007-005711-26-IT Italy
Kanaoka Miwa
2014 - JPRN-jRCTs031180220 -
Keio University, School of Medicine
2017 - JPRN-UMIN000026004 Japan
Peking University First Hospital
2022 Phase 4 ChiCTR2200062766 Beijing
Rabin Medical Center
2010 - NCT01338103 Israel
Research group of rare intractable dermatologial disorder
2010 Phase 2 JPRN-UMIN000004428 Japan
Shandong Provincial Hospital for Skin Diseases & Shandong First Medical University
2023 - ChiCTR2400090625 China
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
2011 Phase 3 NCT01299857 France
2009 Phase 3 NCT00784589 France
University Hospital, Toulouse
2009 - NCT00960713 France
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China
Rituximab and cyclophosphamide IV
Uprety Shraddha
2013 Phase 3 NCT01974518 India
Rituximab injection
University Hospital, Rouen
2023 Phase 4 NCT05898308 -
RO0452294/V02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
RO1061443/F02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States
Silver
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico
Sirolimus
University of California, Irvine
2011 Early Phase 1 NCT01313923 United States
Tofacitinib
Department of Dermatology, the First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086721 China
The First Affiliated Hospital of Army Medical University
2024 Phase 0 ChiCTR2400086698 China
Topical garamycin cream
Cairo University
2022 Phase 3 NCT05594472 Egypt
TPM203
Topas Therapeutics GmbH
2019 Phase 1 EUCTR2019-001727-12-DE Germany;Israel;Italy;United Kingdom
Triamcinolone acetonide
Cairo University
2016 Phase 3 NCT02828163 Egypt
VAY736
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States
Novartis Pharmaceuticals
2013 Phase 2 NCT01930175 Austria;Bulgaria;Germany;Israel;Italy;Taiwan;United Kingdom;United States
Water FOR injection
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany